Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.

摘要: Purpose: Combining siRNA and other chemotherapeutic agents into one nanocarrier can overcome the multidrug resistance (MDR) phenomenon by synergistically MDR relative genes silencing elevated activity. Most of these systems are typically fabricated through complicated procedures, which involves materials preparation, drug loading modifications. Herein, purpose this study is to develop a new fast co-delivery system doxorubicin for potentially synergistic cancer treatment. Methods: The constructed conveniently stable complex consisting bound via intercalation firstly, followed interacting with (3-Aminopropyl)triethoxysilane (APTES) electrostatically Tetraethyl orthosilicate (TEOS) co-condensed, characterizations resultant also investigated. Furthermore, evaluates anti-cancer efficacy in MCF-7/MDR cells after treatment 'two one' nanocarriers. Results: We establish method craft controllable nearly uniform size, entire fabrication process only costs about 10 minutes. presents high capacities doxorubicin, encapsulated plays pH-responsive control release. Further, biological functionality tests synthesized nanocarriers show inhibition P-gp protein encoded MDR-1 gene (a variant human breast cell line resistance) transfection carrying simultaneously, sensitize overall leading improved suppression. Conclusion: Collectively, not serves as potent therapeutics therapy, it may facilitate bench-to-bedside translation combinatorial delivery robust allowing fabricating simply predictable production rate.